Oak Hill Bio has shared a community letter to the Angelman syndrome community with an important update on the next steps of the development of rugonersen.
They are actively preparing to initiate the Phase 3 study in the middle of 2026. Eligibility criteria are available on clinicaltrials.gov; additional details, including study locations, will be updated as they become available.
Read the Letter
